Given the convincing evidence that anti-VEGF monotherapy does not effectively improve survival in glioblastoma patients [22,93], it is imperative to assess the efficacy of multimodal anti-angiogenic therapies. The gene discussed is VEGFA; the disease is glioblastoma.